A Multicenter, Long-term Extension Study to Evaluate the Safety, Tolerability, and Efficacy of AL002 in Participants with Alzheimer's Disease

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506872-29-00

Acronym

AL002-LTE

Enrollment

178

Registered

2023-11-30

Start date

2023-04-13

Completion date

2024-11-25

Last updated

2025-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease

Brief summary

Incidence of AEs, including AESIs and SAEs, Vital signs, clinical laboratory results, and incidence of findings from physical, neurological, ophthalmological examinations, and ECG, C-SSRS, MRI abnormalities, Incidence and severity of ARIA in participants undergoing titration

Interventions

DRUGflorquinitau F18

DRUGPlacebo: sterile solution for intravenous infusion

DRUGHuman ICG1 Monoclonal Antibody Against Trem2

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Incidence of AEs, including AESIs and SAEs, Vital signs, clinical laboratory results, and incidence of findings from physical, neurological, ophthalmological examinations, and ECG, C-SSRS, MRI abnormalities, Incidence and severity of ARIA in participants undergoing titration	—

Countries

France, Germany, Italy, Netherlands, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026